Twist Bioscience Corp. (TWST) intrinsic value & 10-year financials
Twist Bioscience Corp. (TWST) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 55.9% a year to $376.6M, with an average return on invested capital of -15.5%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $132.75
- Market cap
- $7.9B
- Revenue (FY2025)
- $376.6M
- Revenue growth (10-yr CAGR)
- 55.9%
- ROIC (10-yr avg)
- -15.5%
- Free cash flow (FY2025)
- -$75.6M
TWST 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $376.6M | -$77.7M | -$1.30 | -$75.6M | -36.2% | -40.8% |
| FY2024 | $313.0M | -$208.7M | -$3.60 | -$69.2M | -70.6% | -60.3% |
| FY2023 | $245.1M | -$204.6M | -$3.60 | -$170.3M | -88.6% | -47.8% |
| FY2022 | $203.6M | -$217.9M | -$4.04 | -$226.2M | -115.3% | -67.7% |
| FY2021 | $132.3M | -$152.1M | -$3.15 | -$139.3M | -115.4% | -68.3% |
| FY2020 | $90.1M | -$139.9M | -$3.57 | -$152.1M | -155.5% | -72.7% |
| FY2019 | $54.4M | -$107.7M | — | -$102.7M | -200.1% | 136.6% |
| FY2018 | $25.4M | -$71.2M | — | -$69.9M | -277.5% | 25.9% |
| FY2017 | $10.8M | -$59.3M | — | -$57.9M | -543.2% | 55.7% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Twist Bioscience Corp revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Twist Bioscience Corp has historically struggled to out-earn its cost of capital, averaging just -15.5% ROIC.
Twist Bioscience Corp capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Twist Bioscience Corp is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-43.18 per share.